Breaking News

Family Dollar Board Rejects Proposal From Dollar General
Tweet TWEET

bluebird bio to Present at Morgan Stanley Global Healthcare Conference

  bluebird bio to Present at Morgan Stanley Global Healthcare Conference

Morgan Stanley Global Healthcare Conference 2013

Business Wire

CAMBRIDGE, Mass. -- September 4, 2013

bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at
the Morgan Stanley Healthcare Conference to be held September 9 - 11, 2013 at
the Grand Hyatt Hotel, New York, NY. Nick Leschly, Chief bluebird, will
provide an overview of the company at the Morgan Stanley Conference on
Wednesday, September 11, 2013 at 8:00 AM (ET).

To access a simultaneous webcast of Mr. Leschly's overview via the internet,
log on to the "Calendar of Events" section on the Investor and Media page of
the bluebird bio's website at http://investor.bluebirdbio.com. Please connect
to the website at least ten minutes prior to the start of the presentation to
ensure adequate time for a reliable connection and any software download that
may be necessary for the webcast.

A replay of the webcasts will be available on bluebird bio's website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the presentation in
the "Calendar of Events" section of the Investor and Media page of the
bluebird bio's website at http://investor.bluebirdbio.com.

About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic and orphan diseases. bluebird
bio has two clinical-stage programs in development. The most advanced product
candidate, Lenti-D, recently initiated a phase 2/3 study for the treatment of
childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary
neurological disorder affecting young boys. The next most advanced product
candidate, LentiGlobin, is currently in a phase 1/2 study in France for the
treatment of beta-thalassemia major and severe sickle cell disease. A second
phase 1/2 study with LentiGlobin has been initiated in the United States for
the treatment of beta-thalassemia major.

bluebird bio also has an early-stage chimeric antigen receptor-modified T cell
(CAR-T) program for oncology in partnership with Celgene Corporation. bluebird
bio has operations in Cambridge, Massachusetts, San Francisco, California and
Paris, France. For more information, please visit www.bluebirdbio.com.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
regarding the advancement of our clinical trials. Any forward-looking
statements in this press release are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited to, the
risk of cessation or delay of any of the ongoing or planned clinical trials
and/or our development of our product candidates, the risk that the results of
previously conducted studies involving similar product candidates will not be
repeated or observed in ongoing or future studies involving current product
candidates, the risk that our collaboration with Celgene will not continue or
will not be successful, and the risk that any one or more of our product
candidates will not be successfully developed and commercialized. For a
discussion of other risks and uncertainties, and other important factors, any
of which could cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors" in the
final prospectus related to our initial public offering filed with the
Securities and Exchange Commission pursuant to Rule 424(b) of the Securities
Act, as well as discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of the
release, and bluebird bio undertakes no duty to update this information unless
required by law.

Contact:

Investor Relations:
bluebird bio, Inc.
Richard E. T. Smith, Ph.D., 617-588-3321
or
Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
 
Press spacebar to pause and continue. Press esc to stop.